Sign in
4

Changes in Ownership

ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-20-004722

Chief Financial Officer sold 40,313 shares at an average $49.44 ($1,992,925)

  • Chief Financial Officer acquired 33,351 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Myszkowski Kenneth Allen Chief Financial Officer 2020-01-21 Option exercise +33,351 $5.19 $173,092 424,536 D
Myszkowski Kenneth Allen Chief Financial Officer 2020-01-21 Sale −6,397 $47.07 $301,107 418,139 D
Myszkowski Kenneth Allen Chief Financial Officer 2020-01-21 Sale −6,432 $47.93 $308,286 411,707 D
Myszkowski Kenneth Allen Chief Financial Officer 2020-01-21 Sale −10,554 $49.07 $517,885 401,153 D
Myszkowski Kenneth Allen Chief Financial Officer 2020-01-21 Sale −2,800 $49.98 $139,944 398,353 D
Myszkowski Kenneth Allen Chief Financial Officer 2020-01-21 Sale −10,680 $51.11 $545,855 387,673 D
Myszkowski Kenneth Allen Chief Financial Officer 2020-01-21 Sale −3,450 $52.13 $179,849 384,223 D
Derivatives
Myszkowski Kenneth Allen Chief Financial Officer 2020-01-21 Option exercise · Stock Option (right to buy) −33,351 116,116 D
Open-market sales · 40,313 sh · avg $49.44 · $1,992,925
Loading xslF345X03/doc4.xml…